Global Lyophilized Injectable Drugs Market Outlook 2024, Forecast To 2033
8 Mar, 2024
The lyophilized injectable drugs market has shown steady growth, rising from $3.82 billion in 2023 to $3.93 billion in 2024, with a compound annual growth rate (CAGR) of 3.0%. This growth is attributed to an expanding biopharmaceutical industry. Forecasts suggest steady growth, reaching $4.48 billion in 2028, with a CAGR of 3.3%. Factors such as personalized medicine are expected drivers. Major trends include innovation in combination therapies and regulatory emphasis on process validation.
Global Lyophilized Injectable Drugs Market Key Driver
The rising incidence of cardiac disorders globally is fueling demand for lyophilized injectable drugs used in their treatment. With cardiac disorders claiming a significant number of lives annually, the market for lyophilized injectable drugs, offering stability, rapid reconstitution, and reduced contamination risks, is poised for growth. Data from authoritative sources like the Centers for Disease Control and Prevention and New York government underline the severity of cardiac disorders, driving the necessity for effective treatment options such as lyophilized injectable drugs.
Get A Free Sample Of The Global Lyophilized Injectable Drugs Market ReportGlobal Lyophilized Injectable Drugs Market Segments
The lyophilized injectable drugs market covered in this report is segmented –
1) Packaging Type:Specialty Packaging, Point-Of-Care Reconstitution, Single-Use Vials, Other Packaging Types.
2) Type of Delivery:Single-Step Devices, Multi-Step Devices, Prefilled Diluent Syringes, Proprietary Reconstitution Devices.
3) Indication:Infectious Diseases, Autoimmune Diseases, Metabolic Conditions, Other Indications.
4) End-User:Hospitals, Ambulatory Surgery Centers (ASCs), Specialty Clinics, Other End-Users.
By Geography: The countries covered in the lyophilized injectable drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the lyophilized injectable drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyophilized injectable drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Lyophilized Injectable Drugs Industry Players
Pfizer Inc.; Hoffmann-La Roche Ltd; Merck & Co Inc.; Sanofi SA; Novo Nordisk A/S; Becton Dickinson and Company; Baxter International Inc.; Sandoz; Nipro Corporation; B. Braun SE; Aurobindo Pharmaceuticals; Schott AG; Zydus Lifesciences; Recipharm AB; Vetter Pharma-Fertigung GmbH & Co. KG; Fresenius Kabi USA LLC; Vetter Pharma-Fertigung GmbH & Co. KG; CordenPharma International; Aristopharma Limited.; Accord Healthcare; Jubilant HollisterStier LLC; Ciron Drugs & Pharmaceuticals Pvt Ltd.; MSN Laboratories; Qilu pharmaceutical Co Ltd.; Genex Pharma
Get The Full Global Lyophilized Injectable Drugs Market Report
Lyophilized Injectable Drugs Market Overview
Lyophilized injectable drugs, also known as freeze-dried drugs, are medications that have undergone the process of lyophilization. Lyophilization is a technique used to remove water from drugs by freezing them and then subjecting them to a vacuum, causing the frozen water to sublime directly from a solid state to a gas state. Lyophilized injection drugs improve bioavailability, stability, solubility, and patient compliance.